Abstract
Monoclonal antibodies (mAbs) directed against type 2 (T2) inflammatory pathway have revolutionized the treatment of severe eosinophilic asthma (SEA) by improving symptom control and exacerbation frequency, and reducing exposure to oral corticosteroids (OCSs).1,2 Mepolizumab1 and benralizumab2 target IL-5 and IL-5 receptor-alpha (IL-5R), respectively, inhibiting the eosinophilic inflammatory cascades that underpin the pathogenesis of poor symptom control and exacerbation development in SEA.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Allergy and Clinical Immunology: In Practice
Paper Title
Journal
Date
